Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16161191 | 0.96 | KMT2A (0.55) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| Pyrazine SCHEMBL28285881 | 0.94 | KMT2A (0.53) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL14653448 | 0.89 | MEN1 (0.53) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL15626533 | 0.88 | MEN1 (0.52) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL25178278 | 0.87 | MEN1 (0.50) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL16659315 | 0.87 | MEN1 (0.50) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL10042675 | 0.85 | MEN1 (0.48) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL446946 | 0.84 | L3MBTL1 (0.52) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL7210451 | 0.83 | NPC1 (0.47) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL441888 | 0.83 | MAPT (0.59) | MEN1KMT2AALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3986553-B1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2026-01-27 | — | — | US | disclosed |
| EP-3728209-B1 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12466804-B2 | Cyclobutyl carboxylic acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-04-17 | — | — | US | disclosed |
| EP-0471261-B1 | Pyrimidyl-substituted acrylic acid esters | BAYER AG (DE) | 1996-01-17 | — | — | EP | disclosed |
| US-5231097-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | disclosed |
| CN-1060289-A | Mycocide | ICI PLC (GB) | 1992-04-15 | — | — | CN | disclosed |
| EP-0471261-A1 | Pyrimidyl-substituted acrylic acid esters | BAYER AG (DE) | 1992-02-19 | — | — | EP | disclosed |
| EP-0468695-A1 | Fungicides | ZENECA LIMITED (GB) | 1992-01-29 | — | — | EP | disclosed |
| EP-0055583-B1 | ANTIHYPERTENSIVES | Pfizer Limited (GB) | 1985-08-28 | — | — | EP | disclosed |
| US-4483859-A | 4-Amino-6, 7-dimethoxy-2-(4-heteroaryl-piperazino) quinazoline _antihypertensives | PFIZER INC. (US) | 1984-11-20 | — | — | US | disclosed |
| US-4483857-A | 4-Amino-6,7-dimethoxy-2-(4-heteroaryl-piperazino)quinazoline antihypertensives | PFIZER INC. (US) | 1984-11-20 | — | — | US | disclosed |
| US-4435401-A | 4-Amino-6,7-dimethoxy-2-(4-heteroaryl-piperazino)quinazoline antihypertensives | PFIZER INC. (US) | 1984-03-06 | — | — | US | disclosed |
| EP-0055583-A1 | Antihypertensives | Pfizer Limited (GB) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA6, CHRNA7, CHRNA5 | MEN1 4861/4885KMT2A 3415/4885ALDH1A1 1569/4885 |
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | MEN1 895/4885KMT2A 2563/4885ALDH1A1 1133/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | MEN1 3413/4885KMT2A 1722/4885ALDH1A1 3132/4885 |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | MEN1 4437/4885KMT2A 3551/4885ALDH1A1 4315/4885 |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | MEN1 924/4885KMT2A 2316/4885ALDH1A1 1996/4885 |
| US-12466804-B2 | Cyclobutyl carboxylic acids as LPA antagonists | LPAR1, LPAR3, LPAR2 | MEN1 3331/4885KMT2A 3087/4885ALDH1A1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.